Related Experiment Video
Updated: Apr 1, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma
Daniele Alesini1, Claudia Mosillo1, Giuseppe Naso1
1Department of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy.
Abstract:
Everolimus is an oral inhibitor of mammalian target of rapamycin (mTOR-I) and is currently approved for the treatment of metastatic renal cell carcinoma (mRCC) after failure of first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor (TKI). In this narrative review, we aim to report the available evidence about the use of everolimus as second-line therapy for mRCC. A literature search was performed using PubMed/MEDLINE and abstracts from major conferences on clinical oncology as sources. We report data from prospective as well as retrospective and real world data studies and we analyze the safety and efficacy profile of everolimus as second-line therapy for mRCC. Although different drugs are currently available for the second-line treatment of mRCC, everolimus represents a feasible and safe option in this setting, especially for patients who have experienced high-grade toxicity or are still carrying TKI-related toxicities from first-line treatment.
Insights
Everolimus offers a safe and effective second-line treatment option for metastatic renal cell carcinoma (mRCC) patients who have not responded to initial therapies. This review highlights its efficacy and tolerability in the mRCC second-line setting.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) requires effective second-line treatment strategies.
- Vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs) are standard first-line therapy for mRCC.
Purpose of the Study:
- To review the evidence for everolimus as a second-line therapy in mRCC.
- To analyze the safety and efficacy of everolimus in this patient population.
Main Methods:
- A narrative review of published literature.
- Searches conducted on PubMed/MEDLINE and major oncology conference abstracts.
- Inclusion of prospective, retrospective, and real-world data.
Main Results:
- Everolimus is an oral mammalian target of rapamycin inhibitor (mTOR-I).
- Data from various study types support its use in second-line mRCC.
- Everolimus demonstrates a favorable safety and efficacy profile.
Conclusions:
- Everolimus is a feasible and safe option for second-line mRCC treatment.
- It is particularly beneficial for patients with prior TKI toxicity.
- Supports continued use of everolimus in selected mRCC patients.
More Related Videos
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
09:00TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients
Published on: April 13, 2021
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:26Kidney Transplant II: Surgical Procedure
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:16Kidney Transplant III: Nursing Management
01:15Renal Drug Excretion: Overview
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...